China-based biotech Innovent Biologics Inc. (HKG: 1801) announced that the first subject has been dosed in a Phase I clinical study for its IBI324, a bispecific antibody (BsAb) targeting vascular endothelial growth factor A (VEGF-A) and angiopoietin2 (Ang-2) in diabetic macular edema (DME).
Study Details
The Phase I dosage escalation study is designed to assess the safety and tolerability of IBI324 in patients with DME. The drug works by concurrently blocking the dual mechanisms of VEGF-A and Ang-2, achieving anti-angiogenesis effects, stabilizing blood vessels, and inhibiting inflammation.-Fineline Info & Tech
